The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany pauses AstraZeneca COVID shots as a 'precaution'

Mon, 15th Mar 2021 14:46

* German Health Minister Spahn says move precautionary

* PEI cites more new cases of thrombosis

* Spahn expects EMA update following review of shot this
week
(Adds details from Spahn news conference, PEI statement)

BERLIN, March 15 (Reuters) - Germany has suspended use of
AstraZeneca's COVID-19 vaccine, Health Minister Jens
Spahn said on Monday, making it the latest of several European
countries to hit pause following reports of blood coagulation
disorders in recipients.

Spahn said the decision followed a recommendation from the
Paul Ehrlich Institute (PEI), Germany's authority in charge of
vaccines, following newly registered cases of thrombosis.

"The decision today is purely precautionary. It is a purely
technical and not a political decision. And that is why I am
following the recommendation of the Paul Ehrlich Institute
here," Spahn said, adding that cases were very rare.

The PEI said in a statement that more instances of
coagulation disorders had been reported following vaccination
with AstraZeneca's shot since Thursday.

The institute noted a "conspicuous accumulation" of cases of
a very rare cerebral vein thrombosis together with lack of blood
platelets known as thrombocytopenia and bleeding.

The European Medicines Agency (EMA) said on Friday that
several cases of immune thrombocytopenia, a lack of platelets in
the blood that can lead to bleeding and bruising, had been
reported under its vaccine safety monitoring process.

It added at the time it would assess reports of the
condition after vaccines by AstraZeneca, Pfizer/BioNTech
, and Moderna had been given.

Several EU countries have called a halt to the AstraZeneca
vaccine after reports from Denmark and Norway of possible
serious side-effects, including bleeding and blood clots.

Spahn said on Monday the outcome of the review was open and
he was counting on the EMA to come to a decision and
recommendation ideally this week.

The EMA has said that as of March 10, a total of 30 cases of
blood clotting had been reported among close to 5 million people
vaccinated with the AstraZeneca shot in the European Economic
Area, which links 30 European countries.

PEI said people who were still feeling unwell four days
after receiving a dose of AstraZeneca's shot should immediately
seek medical treatment

Many millions of people in Britain have so far received the
British-Swedish pharma company's vaccine.

Spahn said there have been seven reported cases that could
be related to vein thrombosis out of 1.6 million vaccinations in
Germany.

Karl Lauterbach, the main health expert of Chancellor
Merkel’s junior coalition partner SPD, called the suspension a
“big mistake” because it undermined trust in an urgently needed
vaccine.

The health minister for the state of Thuringia called the
decision to halt AstraZeneca vaccinations a "disaster".
(Reporting by Thomas Escritt, Ludwig Burger and Caroline
Copley; Editing by Maria Sheahan and Nick Macfie)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.